Bosulif Approved for Pediatric Patients With Chronic Phase Ph+ CML
The FDA has approved bosulif (bosutinib) for patients aged 1 year or older with chronic phase Ph+ CML.
Hematologic Cancers News
HEMATOLOGIC CANCER ADVISOR
Hematologic Cancers News
State Policies May Prevent Cancer Patients From Using Telehealth
Privately-insured cancer patients living in states with restrictive telehealth policies were less likely to use telehealth in 2020 and 2021, a study showed.
High-Dose Chemo and HSCT Linked to Second Primary Malignancies in Lymphoma Survivors
Lymphoma patients who receive high-dose chemotherapy and autologous HSCT have an increased risk of second primary malignancies, data suggest.
Risk of Albuminuria Higher With Dasatinib Than With Other TKIs
Patients with CML have a higher risk of albuminuria if they receive dasatinib rather than other TKIs, a study suggests.
FDA Fast Tracks TMPRSS6 Inhibitor for Polycythemia Vera
The FDA has granted fast track designation to MWTX-003 (DISC-3405) for the treatment of patients with polycythemia vera.
Cisplatin Shortage Nearly Resolved; Supplies of Carboplatin, Methotrexate Increasing
The US supply of cisplatin is nearly restored, and shortages of carboplatin and methotrexate have been alleviated, the government says.
Ranitidine Does Not Increase the Risk of Cancer, Study Suggests
A meta-analysis suggests that ranitidine does not pose an increased risk of cancer when compared to other histamine-2 receptor antagonists.
Final Results of DREAMM-2 Show Durable Responses With Belantamab Mafodotin
Final results from the DREAMM-2 trial suggest that belantamab mafodotin produces durable responses in patients with relapsed/refractory multiple myeloma.
Ojjaara Approved for Intermediate or High-Risk Myelofibrosis With Anemia
The FDA has approved Ojjaara (momelotinib) for the treatment of intermediate or high-risk myelofibrosis in adults with anemia.
Dose-Intensive Chemoimmunotherapy “Preferred” for Untreated PMBCL
Dose-intensive chemoimmunotherapy may be more effective than standard chemoimmunotherapy in PMBCL, a meta-analysis suggests.
Vitamin C, D Supplementation During Chemo May Reduce Complications in AML
Taking vitamin C and D during chemotherapy may improve some outcomes for patients with AML, a new study suggests.
Aphexda Approved for Stem Cell Mobilization in Multiple Myeloma
Aphexda (motixafortide) is expected to be available later this month.
The Challenge of Making Cancer Trials More Diverse
Patients from racial and ethnic minority groups are still underrepresented in cancer research, despite efforts to make clinical trials more diverse.
Melflufen Demonstrates Efficacy in LIGHTHOUSE Trial; Drug’s Future Still Unclear
Melflufen plus daratumumab and dexamethasone produced better outcomes than daratumumab alone in a phase 3 trial of patients with relapsed/refractory multiple myeloma.
Loncastuximab Tesirine Elicits Lasting Responses in Relapsed/Refractory DLBCL
Loncastuximab tesirine produced durable responses in a phase 2 trial of patients with relapsed or refractory DLBCL.
Oral Mezigdomide and Dexamethasone Proves Active in Rel/Ref Multiple Myeloma
The combination of oral mezigdomide and dexamethasone has shown activity in patients with relapsed/refractory multiple myeloma.
Some Immunosuppressed Patients Lack Anti-Spike Antibodies After Multiple COVID-19 Vaccinations
About 1 in 5 immunosuppressed individuals have no detectable IgG anti-spike antibodies after 3 or more COVID-19 vaccinations, a new study suggests.
Five Things to Know About the New Drug Pricing Negotiations
The Biden administration has picked the first 10 high-priced prescription drugs subject to federal price negotiations.
Some Studies Support Use of Cannabis in Pediatric Cancer; More Research is Needed
There is some evidence to support the use of cannabis for symptom management in children with cancer, but there is a lack of evidence on the safety and efficacy of cannabinoids in this patient population, according to researchers.
Bexmarilimab Gets Orphan Drug Status for AML
Bexmarilimab is a first-in-class, humanized monoclonal antibody designed to target Clever-1, a receptor on macrophages that leads to tumor growth and metastasis.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Chronic Lymphocytic Leukemia
Loading... 
Loading...